Applied Therapeutics Q3 net loss of $19 mln beats expectations

Overview

• Applied Therapeutics Q3 net loss of $19 mln beats analyst expectations

• Company's Q3 operating income also beats analyst expectations

• Research and development expenses decreased by $5.2 mln compared to Q3 2024

Outlook

• Company to meet FDA in 4Q 2025 on govorestat for Classic Galactosemia

• Company plans further FDA meeting for Phase 3 trial design of govorestat in CMT-SORD

• New data supports continued govorestat development for PMM2-CDG

Result Drivers

• R&D - The decrease of approximately $5.2 million was primarily related to a decrease in clinical and preclinical expenses, stock-based compensation, regulatory and other expenses

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Applied Therapeutics Inc is $2.50, about 63.6% above its November 12 closing price of $0.91

Press Release: ID:nGNX3ySWCc

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)